Vaxcyte to Establish Fill-Finish Manufacturing in North Carolina as Key Element of Long-Term United States Commercial Supply Strategy Representing Up to $1 Billion in Manufacturing and Services

Core Insights - Vaxcyte has entered into a new agreement with Thermo Fisher Scientific to enhance domestic manufacturing capacity for its broad-spectrum pneumococcal conjugate vaccines (PCVs) in the U.S. [1][2] - The agreement represents a long-term commitment to U.S. commercial manufacturing, with potential value up to $1 billion [2][3] - This expansion aligns with Vaxcyte's strategy to strengthen its supply chain and support American innovation and jobs [3] Company Overview - Vaxcyte is a clinical-stage vaccine innovation company focused on developing high-fidelity vaccines to combat bacterial diseases [4] - The company's lead candidate, VAX-31, is a 31-valent PCV currently advancing to Phase 3 clinical trials for adults and Phase 2 for infants [4] - Vaxcyte's pipeline also includes VAX-24, VAX-A1, and VAX-GI, targeting various infectious diseases [4]